Citigroup
BRVE

Citigroup’s Braveheart Bio BRVE Stock Holding History

Citigroup’s Portfolio BRVE Stock Details BRVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.6K Buy
+919
New +$24.2K ﹤0.01% 5021

Other funds holding BRVE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Leonard Rickey Investment Advisors
Leonard Rickey Investment Advisors Yakima, Washington $644M AUM 17.66% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Citigroup's BRVE Position: Q3 2026 in Review

Citigroup opened a new position in Braveheart Bio (BRVE) in Q3 2026: 919 shares worth $18.6K. The stake represents ﹤0.01% of the portfolio and ranks #5021 among its holdings.

7 funds tracked by Wall St. Rank hold BRVE as of Q3 2026.

  • Citigroup held 919 shares of Braveheart Bio worth $18.6K as of Q3 2026.
  • Braveheart Bio was a new Citigroup position in Q3 2026.
  • Braveheart Bio made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5021 holding.
  • 7 funds tracked by Wall St. Rank held Braveheart Bio as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.